An interventional study of "BRAXX" Esophageal Brachytherapy Applicator. and Add-on of intraluminal brachytherapy in Esophageal Neoplasms, Head and Neck Neoplasms and Gastrointestinal Neoplasms, sponsored by Taipei Veterans General Hospital, Taiwan. Recruiting at 1 site in Taiwan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-04-15.
Sponsored by Taipei Veterans General Hospital, Taiwan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 79 studies in Esophageal Neoplasms with a site in Taiwan — 17 open to participants now, 29 under way, 2 of them phase 3. Esophageal Neoplasms · Taiwan.
Among the 79 studies in Esophageal Neoplasms with a site in Taiwan, this one is the 61st largest by planned enrollment of the 64 interventional ones that give a count, is one of 7 that started in 2024, is one of 18 with no phase, reaches primary completion later than 2 of the 28 other live ones, and was the 71st registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →17 of the 79 studies in Esophageal Neoplasms with a site in Taiwan are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Taiwan, United States, Australia and 21 more countries
Ages 18+
National Taiwan University Hospital · Sites in Taiwan
Ages 18–99 · Men only
National Taiwan University Hospital · Sites in Taiwan
Ages 18–85
Merck Sharp & Dohme LLC · Sites in Taiwan, United States, Brazil and 9 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in Taiwan, United States, Brazil and 8 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 20 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
79 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 26 · Phase 3 6 · Phase 4 2
First in 2001; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 58 across 1,347 interventional studies indexed under Esophageal Neoplasms.
Median enrollment 98 across the 64 interventional studies, 139 across the 15 observational. Of the 34 that completed or were terminated, 9 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 79 have an industry lead sponsor. The 10 most frequent:
Taipei Veterans General Hospital, Taiwan is the lead sponsor of 338 studies on the registry; 74 are open to participants now.
Taipei Veterans General Hospital, Taiwan has 3 studies filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
10 of the studies in Esophageal Neoplasms with a site in Taiwan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
| NCT05319730Merck Sharp & Dohme LLCA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | 2027-06-11 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
Add all 10 to your calendar (.ics) → With an account.
Among the 79 studies in Esophageal Neoplasms with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to observe the safety and effectiveness of the add-on of intraluminal brachytherapy with BRAXX esophageal brachytherapy applicator after definitive CCRT in patients with thoracic esophageal cancer.
Add-on of intraluminal brachytherapy with applicator:
Brachytherapy protocol starts within 12 weeks after EBRT (This is "week 1"). High-dose-rate (HDR) 5-Gy per fraction is delivered to GTV of esophageal tumor(s), second fraction (if applicable) to be done within 2 weeks after the first fraction, for a total of 5-10Gy in 1-2 fractions. GTV coverage D90 should equal 100% of prescription. It is NOT allowed to give concurrent chemotherapy on the days of HDR brachytherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brachytherapy protocol starts 3 weeks after EBRT (This is "week 1"). After transnasal insertion of the applicator into the esophagus, CT simulation scan(s) with a dummy source in place will be done for further planning procedures, including adjustment of the applicator and 3D treatment planning.
Device: "BRAXX" Esophageal Brachytherapy Applicator. · Radiation: Add-on of intraluminal brachytherapy
The device is intended for use with a commercially available after loader during brachytherapy. The purpose of the device is to deliver a radioactive source to the esophagus. This device is sterile, disposable, and single-use.
Brachytherapy protocol starts within 12 weeks after EBRT. High-dose-rate (HDR) 5-Gy per fraction is delivered to GTV of esophageal tumor(s), second fraction (if applicable) to be done within 2 weeks after the first fraction, for a total of 5-10Gy in 1-2 fractions will be delivered.
To estimate the local control rate at primary tumor site.
Subjects will be followed every 3 months after treatment, EGD-endoscopy (± biopsy) and PET/ CT scans will be arranged in Months 3, 6, 9, and 12 to evaluate the tumor status.
Time frame: 12 months after completion of treatment
To estimate overall response rate.
The overall response rate was observed within 1 year.
Time frame: 12 months after completion of treatment
To estimate distant metastasis rate.
Subjects' distant metastasis rate was observed within 1 year.
Time frame: 12 months after completion of treatment
To estimate progression-free survival rate.
Subjects' progression-free survival rate was observed within 1 year.
Time frame: 12 months after completion of treatment
To estimate overall survival status.
Subjects' overall survival status was observed within 1 year.
Time frame: 12 months after completion of treatment
To estimate toxicity analysis.
All toxicities related to the treatment in this clinical trial will be recorded using the Common Toxicity Criteria version 5.0 developed by the National Cancer Institute.
Time frame: 12 months after completion of treatment
To estimate adverse event.
Adverse events of less severity are reported on case report forms and submitted with routine data submission. A submission of severe adverse effect (SAE) report includes every admission and ER visit of any reason within 3 months of treatment.
Time frame: 3 months after completion of treatment
Started Feb 2024 (actual). Primary completion is estimated for Dec 2024, 10 months after the start.
Of 209 non-industry interventional studies with no phase under Esophageal Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 94. This study's planned 10 months is below that.
Counting every sponsor, half of 218 studies reached it within 46 months; a quarter within 23 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taipei Veterans General Hospital, Taiwan →